Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.

Sanofi acquires Blueprint Medicines for $9.1 billion, gaining Ayvakit, a rare disease treatment approved in the US and EU for multiple conditions.

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant’s fourth major strategic acquisition ...